Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma

Cancer

Volumn 104, Issue 4, 2005, Pages 771-776

  Li, Jiang ^a   El Naggar, Adel ^b   Mao, Li ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Classification; Methylation specific polymerase chain reaction; Salivary gland; Tumorigenesis

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; DNA; PROTEIN P16INK4A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; APOPTOSIS REGULATORY PROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN); RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CELL GROWTH; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; FEMALE; GENE FUNCTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SALIVARY GLAND; TUMOR SUPPRESSOR GENE; GENETICS; METHYLATION; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND TUMOR;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARCINOMA, ADENOID CYSTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; METHYLATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SALIVARY GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 23444447622     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21215     Document Type: Article

References (35)

1. World Health Organization. Histological typing of salivary gland tumors. In: Seifert G, Sobin LH, editors. World Health Organization International histological classification of tumors, 2nd ed. Berlin: Springer-Verlag, 1991:12-28.
2. Ellis GL, Auclair PL. Tumors of the salivary glands. In: Ellis GL, Auclair PL, editors. Atlas of tumor pathology, 3rd ed. Washington, DC: Armed Forces Institute of Pathology, 1996: 57-68, 337-343.
3. Dardick I. Adenoid cystic carcinoma. In: Dardick I, editor. Color atlas/text of salivary gland tumor pathology. New York: IGAKU-SHOIN Medical Publishers, 1996:149-161.
4. Hickman RF, Cawson RA, Duffy SW. The prognosis for specific types of salivary gland tumors. Cancer. 1984;54:1620-1624.
5. Conley J, Dingman DL. Adenoid cystic carcinoma in the head and neck. Arch Otolaryngol Head Neck Surg. 1974;100: 81-90.
6. Spiro RH. The controversial adenoid cystic carcinoma. Clinical consideration. In: McGurk M, Renehan A, editors. Controversies in the management of salivary gland diseases. New York: Oxford University Press, 2001:143-150.
7. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001;293:1089-1093.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Genetics. 2002;3:415-428.
9. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol. 2002;196:1-7.
10. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 1998; 395:237-243.
11. Dammann R, Li C, Yoon J-H, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315-319.
12. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature. 1997;390: 180-184.
13. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res. 1990;233:117-126.
14. 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61:939-942.
15. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res. 2003;9:3635-3640.
16. Mao L. Recent advances in the molecular diagnosis of lung cancer. Oncogene. 2002;21:6960-6969.
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349:2042-2054.
18. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1:61-67.
19. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in Stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1511-1516.
20. Sobin LH, Wittekind C, editors. TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, 2002.
21. Soria J, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002;62:351-355.
22. INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004; 10(18 pt 1):6119-6125.
23. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994;265:415-417.
24. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686-692.
25. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383:907-914.
26. Kim DH, Kim JS, Park JH, et al. Relationship of Ras association domain family 1 methylation and K-Ras mutation in primary non-small cell lung cancer. Cancer Res. 2003;63: 6206-6211.
27. Zochbauer-Muller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer. 2003;107: 612-616.
28. INK4a genes in salivary gland carcinomas. Oncol Rep. 2003;10:555-560.
29. Maruya S, Kurotaki H, Wada R, Saku T, Shinkawa H, Yagihashi S. Promoter methylation and protein expression of the E-cadherin gene in the clinicopathologic assessment of adenoid cystic carcinoma. Mod Pathol. 2004;17:637-645.
30. Uchida D, Begum NM, Almofti A, Kawamata H, Yoshida H, Sato M. Frequent downregulation of 14-3-3 sigma protein and hypermethylation of 14-3-3 sigma gene: in salivary gland adenoid cystic carcinoma. Br J Cancer. 2004;91:1131-1138.
31. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992;164:623-628.
32. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8:229-240.
33. Harbo G, Bundgaard T, Pedersen D, Sogaard H, Overgaard J. Prognostic indicators for malignant tumors of the parotid gland. Clin Otolaryngol. 2002;27:512-516.
34. Batsakis J, Luna MA, El-Naggar A. Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol. 1990;99:1007-1009.
35. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002;62:2370-2377.